Ann: FDA IND Re-Activation Request for Phase Ib/II Trial, page-13

Well, yes that's one thing. Ok, in a tiny nutshell:

- Reactivate trials for ggti-2418
- Transgene will present tg4010 at the end of this month at a big European conference
- Transgene will hopefully have a new partner for tg4010 by the end of the year, but will continue with phase 3 trials themselves regardless. Note here that a new partner will make a big difference to VHL's SP as the downtrend was caused by Novartis not exercising the option to continue the partnership with Transgene.
- Transgene might do something with t4001 if they get a partner for tg4010

So VHL is mainly riding the back of Transgene, hopefully ggti-2418 will give them a bit more control over their own destiny. At least they have cash for a while anyway, I'm in at an average of .9c so bit annoyed I didn't wait to pull the trigger but that's the way it goes sometimes.